Designed by doctors, shaped by you

Get started

What Is the Semaglutide Dose for Weight Loss?

Craig Primack MD

Reviewed by Craig Primack, MD, FACP, FAAP, FOMA

Written by Corinne O'Keefe Osborn

Updated 10/11/2024

The maximum semaglutide dose for weight loss is 2.4 milligrams (mg) per week. Your healthcare provider will start you on a lower weekly dose and gradually increase it over time. 

If you’ve been hearing a lot about GLP-1 receptor agonists like semaglutide, you’re not alone. The popularity of semaglutide, the active ingredient in Ozempic® and Wegovy®, has skyrocketed in recent years. 

Those considering semaglutide for weight loss may wonder about dosing and how to take it. We’re here to help.

Keep reading as we explore semaglutide doses, including information about compounded semaglutide, Ozempic, and Wegovy. And check out our handy semaglutide weight loss dosage chart.

Semaglutide is the active ingredient in three medications approved by the U.S. Food and Drug Administration (FDA): Ozempic, Rybelsus®, and Wegovy. The first two are approved to treat type 2 diabetes and used off-label for weight loss. 

(Off-label use means a medication is prescribed to treat something other than what it’s FDA-approved for.)

Only Wegovy is approved for chronic weight management. It’s intended for people who have obesity and people who are overweight with at least one weight-related condition, such as diabetes, high blood pressure, or high cholesterol

Compounded semaglutide, which is available through the Hers platform, contains the same active ingredient as the brand-name medications (but it hasn’t been approved by the FDA). 

As a weight loss drug, semaglutide is intended to be used along with lifestyle changes like a reduced-calorie diet and regular physical activity.

In stock now

Rx weight loss your way

The maximum semaglutide dosage for weight loss is 2.4 milligrams (mg) weekly. However, that’s not what you’ll take when you first start on semaglutide. 

Semaglutide dosing follows what’s known as a dose escalation scheme. That means your healthcare provider will start you on a lower dose of semaglutide and gradually increase it to a higher dose over time. 

The reason for slowly increasing your weekly doses of semaglutide is to help your body adjust to the medication while minimizing the side effects.

When you start Ozempic or Wegovy, you can expect your dose to be increased by 0.25mg every four weeks. The semaglutide dosing chart below shows the dosing schedule for Wegovy (for weight loss) and Ozempic (for type 2 diabetes).

Dose
Wegovy
Ozempic
Month 1
0.25 mg weekly
0.25 mg weekly
Month 2
0.5 mg weekly
0.5 mg weekly
Month 3
1.0 mg weekly
1.0 mg weekly (if necessary)
Month 4
1.7 mg weekly
1.0 mg weekly
Month 5+
2.4 mg weekly (recommended)
1.0 mg weekly

One of the best things about compounded semaglutide (besides the price) is that it typically comes in vials rather than prefilled injection pens. This gives healthcare providers a lot more flexibility with dosing schedules. 

When you get compounded semaglutide through Hers, your provider will prescribe a personalized dosing schedule tailored just for you. And they can adjust that schedule over time if need be. 

Small dose adjustments can significantly alter your experience with semaglutide — helping you hit that sweet spot between reduced appetite and nausea. 

Making these small dose adjustments with prefilled injection pens is nearly impossible. 

Flexible Dose Options

Ozempic and Wegovy both have a starting dose of 0.25 mg per week. While this may sound small, this medication packs quite a punch. And people can experience uncomfortable side effects.

Your personalized starting dose of compounded semaglutide may be as low as 0.15 mg per week. 

Conversely, if you’re already taking semaglutide and your side effects have gone away, you may start with a semaglutide dose as high as 1.9 mg per week.  

When you get compounded semaglutide through Hers, you’ll get an entirely personalized dose escalation schedule designed to work for your body. Our dosing options are so varied, that we can’t list them all here. But here are a few examples of a dosing schedule that might work for you:

Examples of Weekly Dosing Options
Month 1
Month 2
Month 3
Month 4
Month 5
Month 6
Low Dose Option A
0.2 mg
0.4 mg
0.75 mg
1.25 mg
1.25 mg
1.25 mg
Low Dose Option B
0.15 mg
0.3 mg
0.4 mg
0.8 mg
1.1 mg
1.25 mg
High Dose Option A
0.25 mg
0.5mg
1 mg
1.7 mg
2.4 mg
2.4 mg
High Dose Option B
0.2 mg
0.4 mg
0.8 mg
1.2 mg
1.8 mg
2.2 mg


Once you reach a dose that works for you (you’re losing weight and tolerating the medication well) you’ll stop increasing your dose. This steady dose is known as your maintenance dose. Some people may benefit from the maximum dose of 2.4 mg weekly, but others may never need to go that high. 

Rx Available

Weight loss treatment that puts you first

Semaglutide for weight loss is given as a subcutaneous injection. This means a very thin needle is inserted into the layer of fatty tissue just under the skin. 

Brand-name semaglutide (Wegovy and Ozempic) comes in a prefilled injection pen. This pen is single-use and contains the dose of semaglutide that’s appropriate for you at the time.

Compounded semaglutide often comes in a small vial, in which case you’d measure out the dose each week using a single-use syringe.

When you’re first prescribed semaglutide for weight loss, a healthcare professional will show you how to prepare and give yourself injections.

There are a few areas it can be injected, including the:

  • Abdomen (stomach)

  • Thigh

  • Upper arm

You might want to rotate injection sites with each dose. That means not using the exact same spot over and over again. Rotating injection sites helps to prevent injection site reactions, like bruising, redness, or mild pain.

Semaglutide is supposed to be taken on the same day each week. But missed doses might happen at some point during your treatment journey.

What should you do then? The answer to this question depends on how far away your next dose is.

If your next dose is still more than 48 hours away, take your missed dose as soon as you remember.

But if your next dose is less than 48 hours away, don’t take your missed dose. Instead, wait to take your next dose of semaglutide on the usual day.

As with other GLP-1 receptor agonists, the most common side effects of Wegovy often affect the digestive tract. These can include things like:

  • Nausea

  • Vomiting

  • Diarrhea

  • Constipation

  • Abdominal pain

  • Upset stomach

Gastrointestinal side effects usually arise during periods of dose escalation as your body adjusts to more semaglutide. 

They might go away shortly after you reach your maintenance dose, but it’s different for everyone.

Other potential side effects of Wegovy include:

  • Fatigue

  • Headache

  • Dizziness

  • Belching and flatulence

  • Distended abdomen (visible bloating)

  • Low blood sugar (hypoglycemia) in people who also have type 2 diabetes

  • Gastroesophageal reflux disease (GERD)

  • Inflammation of the digestive tract (gastroenteritis)

  • Inflamed nose and throat (nasopharyngitis)

There are also rarer adverse effects that can happen when taking Wegovy. According to the drug’s prescribing information, these potential risks are:

  • An allergic reaction (hypersensitivity)

  • Severe low blood sugar in people with type 2 diabetes, especially those taking insulin or sulfonylureas

  • Complications related to diabetic retinopathy in those with type 2 diabetes

  • Acute pancreatitis or gallbladder disease

  • Acute kidney injury

  • Increases in heart rate

  • Suicidal ideation or behavior

Lastly, Wegovy may increase the risk of certain thyroid tumors — but this has only been observed in rodent studies. Still, definitely tell your healthcare provider if you have a personal or family history of thyroid cancer before starting semaglutide treatment.

It’s possible to experience significant, disruptive side effects while taking semaglutide for weight loss. Clinical trials have reported discontinuation rates (people quitting the medication) of up to eight percent due to gastrointestinal side effects.

Some research suggests that discontinuation rates for GLP-1s may be significantly higher in the real world, particularly in people with obesity.

It’s totally valid to wonder what happens next if you have significant side effects while taking semaglutide for weight loss. There are several possibilities.

  • First, if you’ve reached your maintenance dose but aren’t tolerating it well, your provider might reduce your dose.

  • Another option is to try a different GLP-1 receptor agonist to help with weight loss. Zepbound® (tirzepatide) and Saxenda® (liraglutide) are two other options FDA-approved for weight management.

  • It’s also possible that GLP-1 receptor agonists may not be the optimal weight management intervention for you. Depending on your individual situation, other weight loss medications (like weight loss pills) or bariatric surgery might be worth exploring.

In any case, your healthcare provider is there to support you. They can work with you to address any questions or concerns that pop up during your weight loss journey.

Weight Loss Treatments

Weight loss, unlocked

Here’s what to remember about the semaglutide dose for weight loss:

  • Semaglutide injections are usually prescribed on a dose escalation scheme, meaning you start low and gradually increase your dosage.

  • The starting dose of Wegovy is typically 0.25 milligrams, and the maximum dose is 2.4 milligrams.

  • Compounded semaglutide comes in vials instead of prefilled pens, making personalized dosing schedules easier. 

  • Typically, semaglutide doses are increased every four weeks if the medication is well tolerated. 

  • If you experience prolonged or significant side effects, you might benefit from a slower dose escalation scheme or a lower maintenance dose.

If you’re interested in compounded semaglutide injections, start by taking our free online weight loss assessment.

This article is for informational purposes only and does not constitute medical advice. The information contained herein is not a substitute for and should never be relied upon for professional medical advice. Always talk to your doctor about the risks and benefits of any treatment. Learn more about our editorial standards here.

14 Sources

  1. Do D, et al. (2024). GLP-1 receptor agonist discontinuation among patients with obesity and/or type 2 diabetes. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2819256
  2. Ghusn W, et al. (2022). Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486455/
  3. Gorgojo-Martinez JJ, et al. (2023). Clinical recommendations to manage gastrointestinal adverse effects in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821052/
  4. Kommu S, et al. (2024). Semaglutide. https://www.ncbi.nlm.nih.gov/books/NBK603723/
  5. National Heart, Lung, and Blood Institute (NHLBI). (n.d.). https://www.nhlbi.nih.gov/health/educational/lose_wt/BMI/bmicalc.htm
  6. Saxenda (liraglutide) injection, for subcutaneous use. (2024). https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206321s012s013s014lbl.pdf
  7. Scannell C, et al. (2024). Prescription fills for semaglutide products by payment method. https://jamanetwork.com/journals/jama-health-forum/fullarticle/2821688
  8. Singh G, et al. (2022). Wegovy (semaglutide): A new weight loss drug for chronic weight management. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717485/
  9. U.S. Food and Drug Administration (FDA). (2024). FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
  10. U.S. Food and Drug Administration (FDA). (2021). FDA approves new drug treatment for chronic weight management, first since 2014. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014
  11. U.S. Food and Drug Administration (FDA). (2021). FDA approves new medication for chronic weight management. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
  12. U.S. Food and Drug Administration (FDA). (2020). Medications containing semaglutide marketed for type 2 diabetes or weight loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss
  13. Wegovy (semaglutide) injection, for subcutaneous use. (2023). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
  14. Wilding JPH, et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
Editorial Standards

Hims & Hers has strict sourcing guidelines to ensure our content is accurate and current. We rely on peer-reviewed studies, academic research institutions, and medical associations. We strive to use primary sources and refrain from using tertiary references. See a mistake? Let us know at [email protected]!

This article is for informational purposes only and does not constitute medical advice. The information contained herein is not a substitute for and should never be relied upon for professional medical advice. Always talk to your doctor about the risks and benefits of any treatment. Learn more about our editorial standards here.

Related Articles

Find your medication kit

Personalized ingredients for personalized care